



Image

16/35
\$

Attorney Docket No.: UBC.P-020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gleave et al.
Serial No.: 09/913,325
Confirmation: 8469
Filed: 8/10/2001
Title: TRPM-2 Antisense Therapy

SUBMISSION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

Enclosed is the Credit Card form for payment of submission of this document. No other fees are believed due, however, the Commissioner is authorized to charge any additional fees which might be due to Deposit Account No. 15-0610.

04/14/2004 FFANAEIA 00000071 09913325

01 FC:1806

180.00 OP

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina T. Larson

Marina T. Larson, Ph.D, Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
Ph.: 970-468-6600 Fax: 970-468-0104


CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this paper and the attachments mentioned herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 12, 2004

Anne Wagner
Anne Wagner

April 12, 2004
Date of Signature



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Use as many sheets as necessary)

Application Number	09/913,325
--------------------	------------

Filing Date	8/10/2001
-------------	-----------

First Named Inventor	Gleave et al.
----------------------	---------------

Art Unit	1635
----------	------

Examiner Name	Karen Lacourciere
---------------	-------------------

Attorney Docket Number	UBC.P-020
------------------------	-----------


[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
		WO 00/49937	8/31/2000	The University of British Columbia	Appear	
		WO 02/22635 A1	3/21/2002	ISIS Pharmaceuticals, Inc.		
		WO 03/062421 A1	7/31/2003	The University of British Columbia		
		WO 03/072591 A1	9/4/2003	University of British Columbia		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/913,325
Filing Date	8/10/2001
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Karen Lacourciere
Attorney Docket Number	UBC:P-020

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, 2001, Page(s) 39-49, Publisher: Elsevier Science Inc.	
		GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, Page(s) 79-92, Volume 21, Publisher: Kluwer Academic Publishers	
		GLEAVE ET AL., Targeting anti-apoptotic genes unregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen - and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Publisher: Kluwer Academic Publishers	
		GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, Page(s) 209-221, Volume 4	
		JONES ET AL., Molecules in focus Clusterin, The International Journal of Biochemistry and Cell Biology, 2002, Page(s) 427-431, Volume 34	
		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, Page(s) 337-349, Volume 8	
		MIYAKE ET AL., Synergistic Chemosensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model ¹ , Clinical Cancer Research, 12/2001, Page(s) 4245-4251, Volume 7	
		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both <i>in Vitro</i> and <i>in Vivo</i> ¹ , Clinical Cancer Research, 5/2000, Page(s) 1655-1663, Volume 6	
		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, International Journal of Biochemistry, 1995, Page(s) 633-645, Volume 27, Number 7, Publisher: Elsevier Science Ltd.	
		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Frontiers, 3/2000, Page(s) 95-98	
		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.